US Patient Site

You may save substantial time for your HER2+ breast cancer patients and practice with PHESGO1-3

PHESGO combines PERJETA® (pertuzumab) and trastuzumab into a single subcutaneous injection that’s administered in ~5 minutes*1

Faster administration with PHESGO vs IV PERJETA + IV trastuzumab*1,2

  • Patients should be observed for a minimum of 30 minutes after initial dose of PHESGO and 15 minutes after each maintenance dose of PHESGO for signs of hypersensitivity symptoms or administration-related reactions. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use

*Refers to actual injection time of PHESGO vs infusion time of IV PERJETA + trastuzumab and does not account for all aspects of treatment. Does not include observation time. Actual clinic time may vary. PERJETA and trastuzumab can be given in any order.1,2 Please see the PERJETA full Prescribing Information for additional dosing information for PERJETA + trastuzumab.

PHESGO gives you an opportunity to save time for your patients and practice1,2

Observed Times of PHESGO vs IV PERJETA + IV trastuzumab in a Time & Motion Study3

Time & Motion Study Design
  • The Time & Motion study is a prospective, pre-specified substudy of ADEPT. ADEPT is a single-arm Phase 2 study of patients with HER2+ early breast cancer. The Time & Motion study enrolled 22 patients after their initial loading dose of PHESGO
  • Each patient in the Time & Motion study received 4 maintenance doses: 2 cycles of IV PERJETA + IV trastuzumab followed by 2 cycles of PHESGO (88 total cycles evaluated)
  • Study objective: Estimate the relative difference in time and logistical burden between IV PERJETA + IV trastuzumab and PHESGO
    • Primary endpoint: Patient chair time
    • Secondary exploratory endpoints: Patient time in clinic, drug administration time, pharmacy drug preparation time

Time & Motion Limitations and Considerations

  • Performed at a single US institution (Dana Farber Cancer Institute). Results may not be generalizable to other centers
  • Protocol allowed for shorter observation time after IV PERJETA administration than specified in the PERJETA USPI
  • Evaluated maintenance doses only and did not review differences in loading dose times

PHESGO time savings for HCPs, patients, and pharmacists vs IV PERJETA + IV trastuzumab3

SD=standard deviation.
†Patients were evaluated from the start of first drug administration to the end of the final post-drug observation period.
‡Patients were evaluated from the infusion room check-in time to the end of the final post-drug observation period. Administration time was also studied and is a component of the chair time and total patient time in clinic endpoints.
§Total pharmacy prep time was evaluated from order receipt by pharmacy to drug leaving the pharmacy.

Illustration of woman showing injection site at the left or right thigh

In this Time & Motion study, treating patients with PHESGO took on average less than a third of the chair time needed to treat with IV PERJETA + IV trastuzumab3

NEXT: SEE NCCN GUIDELINES® FOR PHESGO
Image that shows PHESGO as a syringe icon and Perjeta + trastuzumab in IV bag icons

PHESGO is FDA approved for all of the same HER2+ breast cancer indications as PERJETA.1,2

LEARN MORE
Image of a shield with plus sign icon in the middle

Most major insurance plans provide coverage for PHESGO*4

*Data current as of June 2025. Insurer policies may vary and are subject to change.

LEARN MORE
Click here to learn more about the dosing and administration of fixed-dose PHESGO
SEE DOSING & ADMINISTRATION

    • PHESGO Prescribing Information. Genentech, Inc. 2024.

      PHESGO Prescribing Information. Genentech, Inc. 2024.

    • PERJETA Prescribing Information. Genentech, Inc. 2025.

      PERJETA Prescribing Information. Genentech, Inc. 2025.

    • Waks AG, Chen EL, Graham N, et al. Subcutaneous vs intravenous trastuzumab/pertuzumab: a time and motion substudy of a phase II trial of adjuvant trastuzumab/pertuzumab for stage I HER2+ breast cancer (ADEPT trial). J Oncol Pract. 2025;21(3):351-357 and Supplementary Material. doi:10.1200/OP.24.00021

      Waks AG, Chen EL, Graham N, et al. Subcutaneous vs intravenous trastuzumab/pertuzumab: a time and motion substudy of a phase II trial of adjuvant trastuzumab/pertuzumab for stage I HER2+ breast cancer (ADEPT trial). J Oncol Pract. 2025;21(3):351-357 and Supplementary Material. doi:10.1200/OP.24.00021

    • Data on file. Genentech, Inc. MMIT Analysis. HLI Lives Database.

      Data on file. Genentech, Inc. MMIT Analysis. HLI Lives Database.

    Important Safety Information & Indications

    Indications

    Early Breast Cancer

    PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with chemotherapy for

    • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC)
    • the adjuvant treatment of adult patients with HER2-positive early breast cancer (EBC) at high risk of recurrence

    Select patients for therapy based on an FDA-approved companion diagnostic test.

    Metastatic Breast Cancer

    PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

    Select patients for therapy based on an FDA-approved companion diagnostic test.

    BOXED WARNINGS: Cardiomyopathy, Embryo-Fetal Toxicity, and Pulmonary Toxicity

    • PHESGO administration can result in subclinical and clinical cardiac failure. The incidence and severity were highest in patients receiving PHESGO with anthracycline-containing chemotherapy regimens. Evaluate cardiac function prior to and during treatment with PHESGO. Discontinue PHESGO treatment in patients receiving adjuvant therapy and withhold PHESGO in patients with metastatic disease for clinically significant decrease in left ventricular function

    • Exposure to PHESGO can result in embryo-fetal death and birth defects, including oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception

    • PHESGO administration can result in serious and fatal pulmonary toxicity. Discontinue PHESGO for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Monitor patients until symptoms completely resolve

    Contraindications

    PHESGO is contraindicated in patients with known hypersensitivity to pertuzumab, or trastuzumab, or hyaluronidase, or to any of its excipients.

    Additional Important Safety Information

    Cardiomyopathy

    • PHESGO administration can result in subclinical and clinical cardiac failure. The incidence and severity were highest in patients receiving PHESGO with anthracycline-containing chemotherapy regimens. An increased incidence of left ventricular ejection fraction (LVEF) decline has been observed in patients treated with intravenous pertuzumab, intravenous trastuzumab, and docetaxel

    • PHESGO can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death

    • PHESGO can also cause asymptomatic decline in LVEF

    • Patients who receive anthracycline after stopping PHESGO may also be at increased risk of cardiac dysfunction

    • Discontinue PHESGO treatment in patients receiving adjuvant therapy and withhold PHESGO in patients with metastatic disease for clinically significant decrease in left ventricular function

    Cardiac Monitoring

    • Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of PHESGO

    • Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan

    • Monitor frequently for decreased left ventricular function during and after PHESGO treatment

    • Monitor more frequently if PHESGO is withheld for significant left ventricular cardiac dysfunction

    Embryo-Fetal Toxicity

    • PHESGO can cause fetal harm when administered to a pregnant woman. In post-marketing reports, use of intravenous trastuzumab during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. In an animal reproduction study, administration of intravenous pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death at exposures 2.5 to 20 times the exposure in humans at the recommended dose, based on Cmax

    • Verify the pregnancy status of females of reproductive potential prior to the initiation of PHESGO. Advise pregnant women and females of reproductive potential that exposure to PHESGO during pregnancy or within 7 months prior to conception can result in fetal harm. Advise females of reproductive potential to use effective contraception during treatment and for 7 months following the last dose of PHESGO

    • There is a pregnancy pharmacovigilance program for PHESGO. If PHESGO is administered during pregnancy, or if a patient becomes pregnant while receiving PHESGO or within 7 months following the last dose of PHESGO, health care providers and patients should immediately report PHESGO exposure to Genentech at 1-888-835-2555

    Pulmonary Toxicity

    • PHESGO can cause serious and fatal pulmonary toxicity. These adverse reactions have been reported with intravenous trastuzumab

    • Pulmonary toxicity includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity

    Exacerbation of Chemotherapy-Induced Neutropenia

    • PHESGO may exacerbate chemotherapy-induced neutropenia. In randomized controlled clinical trials with intravenous trastuzumab, Grade 3-4 neutropenia and febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not

    Hypersensitivity and Administration-Related Reactions

    • Severe administration-related reactions (ARRs), including hypersensitivity, anaphylaxis, and events with fatal outcomes, have been associated with intravenous pertuzumab and trastuzumab. Patients experiencing dyspnea at rest due to complications of advanced malignancy and comorbidities may be at increased risk of a severe or of a fatal ARR

    • In the FeDeriCa trial the incidence of hypersensitivity was 1.2% in the PHESGO arm. ARRs occurred in 21% of patients who received PHESGO. In the PHESGO arm, the most common ARRs were injection site reaction (15%) and injection site pain (2%)

    • Closely monitor patients during and for 30 minutes after the injection of initial dose and during and for 15 minutes following subsequent injections of maintenance dose of PHESGO. If a significant injection-related reaction occurs, slow down or pause the injection and administer appropriate medical therapies. Evaluate and carefully monitor patients until complete resolution of signs and symptoms

    • Permanently discontinue treatment with PHESGO in patients who experience anaphylaxis or severe injection-related reactions. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use. For patients experiencing reversible Grade 1 or 2 hypersensitivity reactions, consider pre-medication with an analgesic, antipyretic, or an antihistamine prior to readministration of PHESGO

    Most Common Adverse Reactions

    Early Breast Cancer

    The most common adverse reactions (>30%) with PHESGO were alopecia, nausea, diarrhea, anemia, and asthenia.

    Metastatic Breast Cancer (based on IV pertuzumab)

    The most common adverse reactions (>30%) with pertuzumab in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.

    You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

    Please see full Prescribing Information for additional Important Safety Information, including BOXED WARNINGS.